Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: Evidence for herd effects and strain replacement due to Hib vaccination

Vaccine

Volumn 28, Issue 24, 2010, Pages 4073-4078

  Adam, H J ^a   Richardson, S E ^b,c,d   Jamieson, F B ^b,c   Rawte, P ^b   Low, D E ^b,c,e   Fisman, D N ^f  

^a HEALTH SCIENCES CENTRE   (Canada)

^b PUBLIC HEALTH ONTARIO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Haemophilus influenzae; Hib vaccination; Strain replacement

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIUM ISOLATE; CANADA; CHILD; CONTROLLED STUDY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE TYPE A; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS INFLUENZAE TYPE C; HAEMOPHILUS INFLUENZAE TYPE D; HAEMOPHILUS INFLUENZAE TYPE E; HAEMOPHILUS INFLUENZAE TYPE F; HUMAN; IMMUNIZATION; INFECTION RATE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEROTYPING; STRAIN DIFFERENCE; TREND STUDY;

ADOLESCENT; ADULT; AGED; BACTERIAL CAPSULES; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INCIDENCE; MIDDLE AGED; ONTARIO; SEROTYPING; YOUNG ADULT;

EID: 77952584729     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.075     Document Type: Article

References (27)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clinical Microbiology Reviews 13 (2000) 302-317
2. Scheifele D.W., Bettinger J.A., Halperin S.A., Law B., and Bortolussi R. Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007. Pediatric Infectious Diseases Journal 27 (2008) 755-757
3. Dagan R., Fraser D., Roitman M., Slater P., Anis E., Ashkenazi S., et al. Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Vaccine 17 (1999) 134-141
4. Hviid A., and Melbye M. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 22 (2004) 378-382
5. Ulanova M., and Tsang R.S. Invasive Haemophilus influenzae disease: changing epidemiology and host-parasite interactions in the 21st century. Infection, Genetics and Evolution 9 (2009) 594-605
6. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 6571-6576
7. McConnell A., Tan B., Scheifele D., Halperin S., Vaudry W., Law B., et al. Invasive infections caused by Haemophilus influenzae serotypes in twelve Canadian IMPACT centers, 1996-2001. Pediatric Infectious Diseases Journal 26 (2007) 1025-1031
8. Tsang R.S., Mubareka S., Sill M.L., Wylie J., Skinner S., and Law D.K. Invasive Haemophilus influenzae in Manitoba, Canada, in the postvaccination era. Journal of Clinical Microbiology 44 (2006) 1530-1535
9. Brown V.M., Madden S., Kelly L., Jamieson F.B., Tsang R.S., and Ulanova M. Invasive Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 2002-2008. Clinical Infectious Diseases 49 (2009) 1240-1243
10. Kilian M. Haemophilus. In: Murray P.R., Baron E.J., Jorgensen J.H., Landry M.L., and Pfaller M.A. (Eds). Manual of clinical microbiology. 9th ed. Vol. 1 (2007), ASM Press, Washington 636-648
11. Szklo M., and Nieto J. Dealing with threats to validity. In: Szklo M., and Nieto J. (Eds). Epidemiology: beyond the basics. 1st ed. (2000), Aspen Press, Gaithersburg 255-341
12. Statistics Canada. Population and dwelling counts for Canada, Provinces, Territories, and census divisions, http://www12.statcan.ca/english/census06/data/popdwell/Table.cfm?T=702&PR=35&SR=1&S=3&O=D; 2001 [accessed 04.06.09].
13. Stats Canada. Population and dwelling counts for Canada, Provinces, Territories, and census divisions. http://www12.statcan.ca/english/census06/data/popdwell/Table.cfm?T=702&PR=35&SR=1&S=3&O=D; 2001. [accessed 04.06.09].
14. Thompson S. Why and how sources of heterogeneity should be investigated. In: Egger M., Davey-Smith G., and Altman D.M.E. (Eds). Systematic reviews in health care: meta-analysis in context. 2nd ed. (2001), BMJ Books, London 157-175
15. Barbour M.L. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerging Infectious Diseases 2 (1996) 176-182
16. Trotter C.L., McVernon J., Ramsay M.E., Whitney C.G., Mulholland E.K., Goldblatt D., et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26 (2008) 4434-4445
17. Peltola H., Aavitsland P., Hansen K.G., Jonsdottir K.E., Nokleby H., and Romanus V. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. Journal of Infectious Diseases 179 (1999) 223-229
18. Barbour M.L., Booy R., Crook D.W., Griffiths H., Chapel H.M., Moxon E.R., et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatric Infectious Diseases Journal 12 (1993) 478-484
19. Takala A.K., Eskola J., Leinonen M., Kayhty H., Nissinen A., Pekkanen E., et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. Journal of Infectious Diseases 164 (1991) 982-986
20. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. Morbidity and Mortality Weekly Report 2007; 56:1077-80.
21. Kinlin L.M., Jamieson F., Brown E.M., Brown S., Rawte P., Dolman S., et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 27 (2009) 1735-1740
22. Campos J., Hernando M., Roman F., Perez-Vazquez M., Aracil B., Oteo J., et al. Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b. Journal of Clinical Microbiology 42 (2004) 524-529
23. Dworkin M.S., Park L., and Borchardt S.M. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons>or=65 years old. Clinical Infectious Diseases 44 (2007) 810-816
24. Perdue D.G., Bulkow L.R., Gellin B.G., Davidson M., Petersen K.M., Singleton R.J., et al. Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. Journal of the American Medical Association 283 (2000) 3089-3094
25. Urwin G., Krohn J.A., Deaver-Robinson K., Wenger J.D., and Farley M.M. Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H. influenzae serotype b vaccine era. The Haemophilus influenzae study group. Clinical Infectious Diseases 22 (1996) 1069-1076
26. Campos J., Roman F., Perez-Vazquez M., Aracil B., Oteo J., and Cercenado E. Antibiotic resistance and clinical significance of Haemophilus influenzae type f. Journal of Antimicrobial Chemotherapy 52 (2003) 961-966
27. Sciberras J. Invasive Haemophilus influenzae serotype b surveillance in Ontario-documenting the progression towards elimination. Canada Communicable Disease Report 25 (1999) 181-184